Display options
Cite
Edupuganti S, C De Rosa S, Elizaga M, et al. Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP. Vaccines (Basel). 2020;8(4)doi: 10.3390/vaccines8040741.
Edupuganti, S., C De Rosa, S., Elizaga, M., Lu, Y., Han, X., Huang, Y., Swann, E., Polakowski, L., A Kalams, S., Keefer, M., Maenza, J., C Wise, M., Yan, J., Morrow, M. P., Khan, A. S., Boyer, J. D., Humeau, L., White, S., Sardesai, N. Y., Bagarazzi, M. L., Gilbert, P. B., Kublin, J. G., Corey, L., Weiner, D. B., On Behalf Of The Hvtn Study Team, & The Niaid-Funded Hiv Vaccine Trials Network. (2020). Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP. Vaccines, 8(4), . https://doi.org/10.3390/vaccines8040741
Edupuganti, Srilatha, et al. "Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP." Vaccines vol. 8,4 (2020). doi: https://doi.org/10.3390/vaccines8040741
Edupuganti S, C De Rosa S, Elizaga M, Lu Y, Han X, Huang Y, Swann E, Polakowski L, A Kalams S, Keefer M, Maenza J, C Wise M, Yan J, Morrow MP, Khan AS, Boyer JD, Humeau L, White S, Sardesai NY, Bagarazzi ML, Gilbert PB, Kublin JG, Corey L, Weiner DB, On Behalf Of The Hvtn Study Team, The Niaid-Funded Hiv Vaccine Trials Network. Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP. Vaccines (Basel). 2020 Dec 07;8(4). doi: 10.3390/vaccines8040741. PMID: 33297341; PMCID: PMC7762306.
Copy Download .nbib Format: NLM
Share it on

Vaccines (Basel). 2020 Dec 07;8(4). doi: 10.3390/vaccines8040741.

Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP.

Vaccines

Srilatha Edupuganti, Stephen C De Rosa, Marnie Elizaga, Yiwen Lu, Xue Han, Yunda Huang, Edith Swann, Laura Polakowski, Spyros A Kalams, Michael Keefer, Janine Maenza, Megan C Wise, Jian Yan, Matthew P Morrow, Amir S Khan, Jean D Boyer, Laurent Humeau, Scott White, Niranjan Y Sardesai, Mark L Bagarazzi, Peter B Gilbert, James G Kublin, Lawrence Corey, David B Weiner, On Behalf Of The Hvtn Study Team, The Niaid-Funded Hiv Vaccine Trials Network

Affiliations

  1. Division of Infectious Disease, Department of Medicine, Emory University, Atlanta, GA 30322, USA.
  2. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
  3. Department of Laboratory Medicine, University of Washington, Seattle, WA 98195, USA.
  4. Department of Global Health, University of Washington, Seattle, WA 98195, USA.
  5. Division of AIDS, NIH, Bethesda, MD 20892, USA.
  6. Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  7. Department of Medicine, University of Rochester School of Medicine & Dentistry, Rochester, NY 14642, USA.
  8. Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA 98195, USA.
  9. Inovio Pharmaceuticals Inc. Plymouth Meeting, PA 19462, USA.
  10. Wistar Institute, Philadelphia, PA 19104, USA.

PMID: 33297341 PMCID: PMC7762306 DOI: 10.3390/vaccines8040741

Abstract

METHODS: The HVTN 098 trial assessed the PENNVAX

RESULTS: HVTN 098 enrolled 94 participants: 85 received PENNVAX

CONCLUSIONS: ID/EP and IM/EP are distinct experiences; however, HIV-1 DNA vaccination by either route was safe, tolerable and acceptable by most study participants.

Keywords: DNA vaccine; HIV vaccine; IL-12; electroporation; intradermal; intramuscular; safety

References

  1. Curr Opin Immunol. 2011 Jun;23(3):421-9 - PubMed
  2. Biochem Biophys Res Commun. 1999 Aug 2;261(2):377-80 - PubMed
  3. Methods Mol Biol. 2014;1121:279-89 - PubMed
  4. Hum Gene Ther Methods. 2018 Aug;29(4):177-188 - PubMed
  5. Nat Immunol. 2012 Jul 19;13(8):722-8 - PubMed
  6. Ann Emerg Med. 1996 Apr;27(4):427-32 - PubMed
  7. J Infect Dis. 2019 Jul 2;220(3):400-410 - PubMed
  8. PLoS One. 2015 Aug 07;10(8):e0134287 - PubMed
  9. Expert Rev Vaccines. 2015 Feb;14(2):195-204 - PubMed
  10. Immunotherapy. 2017 Dec;9(16):1309-1321 - PubMed
  11. Chest. 1999 Nov;116(5):1208-17 - PubMed
  12. J Infect Dis. 2013 Sep 1;208(5):818-29 - PubMed
  13. PLoS One. 2012;7(1):e29231 - PubMed
  14. N Engl J Med. 2004 Nov 25;351(22):2295-301 - PubMed
  15. JCI Insight. 2020 Jul 9;5(13): - PubMed
  16. N Engl J Med. 2017 Oct 4;: - PubMed
  17. Vaccine. 2004 Apr 16;22(13-14):1744-50 - PubMed
  18. Vaccine. 2008 Sep 19;26(40):5230-7 - PubMed
  19. Hum Vaccin Immunother. 2013 Oct;9(10):2246-52 - PubMed
  20. PLoS One. 2018 Sep 20;13(9):e0202753 - PubMed
  21. Curr Gene Ther. 2007 Feb;7(1):67-77 - PubMed
  22. Vaccine. 2015 May 11;33(20):2347-53 - PubMed
  23. J Interferon Cytokine Res. 1998 Jul;18(7):537-47 - PubMed
  24. PLoS One. 2014 Mar 12;9(3):e91366 - PubMed
  25. Vaccine. 2012 Oct 5;30(45):6427-35 - PubMed
  26. J Immunol. 2005 Jul 1;175(1):112-23 - PubMed
  27. J Infect Dis. 2006 Dec 15;194(12):1650-60 - PubMed
  28. Curr Opin Immunol. 2020 Aug;65:21-27 - PubMed
  29. Springer Semin Immunopathol. 2006 Nov;28(3):267-79 - PubMed
  30. Immunol Rev. 2004 Jun;199:84-99 - PubMed
  31. J Infect Dis. 2017 Nov 27;216(9):1080-1090 - PubMed
  32. PLoS One. 2011;6(5):e19252 - PubMed
  33. Lancet. 2015 Nov 21;386(10008):2078-2088 - PubMed
  34. J Virol. 2014 Jun;88(12):6959-69 - PubMed
  35. J Empir Res Hum Res Ethics. 2016 Oct;11(4):299-310 - PubMed

Publication Types

Grant support